Rotigotine: 4 agencies, 2007–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 16.9 years separate the first record, 31 Jan 2007 at HAS (France), from the most recent, 22 Dec 2023 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: restricted on 13 Aug 2007, recommended by 10 Aug 2009.
No assessment is on file from PBAC (Australia), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
HAS (France) was first to assess rotigotine, on 31 Jan 2007; PHARMAC (New Zealand) did not open a file until 6 Nov 2014 — a wide spread of 7.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
Restriction is doing real work here: 3 of 9 decisive outcomes narrowed rotigotine to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
4 of the 4 agencies here assessed rotigotine more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed rotigotine.
The full ledger for rotigotine reads 5 recommended, 4 other, 3 restricted and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 22 Dec 2023 | Parkinson's disease | PTAC advice: High | source |
| PHARMAC (New Zealand) | 21 Jun 2023 | Restless leg syndrome | PTAC advice: Cost Neutral | source |
| HAS (France) | 18 Sep 2013 | Indication extension | ASMR IV | source |
| TLV (Sweden) | 29 Jun 2010 | Neupro inte in i högkostnadsskyddet för RLS | rejection or exclusion | source |
| SMC (Scotland) | 13 Aug 2007 | advanced-stage idiopathic Parkinsons disease | accepted (restricted) | source |
8 further decisions for rotigotine, across 4 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- levodopa — same ATC class N04B — Anti-parkinson
- pramipexole — same ATC class N04B — Anti-parkinson
- rasagiline — same ATC class N04B — Anti-parkinson
- ropinirole — same ATC class N04B — Anti-parkinson
- safinamide — same ATC class N04B — Anti-parkinson
- osimertinib — also decided by PHARMAC in 2023Q4
Coverage: 13 decisions for rotigotine from 4 agencies, 2007 to 2023. Data to 7 Sep 2026. ATC class N04B — Anti-parkinson. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.